Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to ...

Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in ...

Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at ...

Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time ...

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to ...

Atorvastatin reduce​​d​​ major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or ...

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and ...

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial ...

A registry-based digital strategy that identified untreated patients and invited them to a telephone consultation more than ...

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional ...

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary ...